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BACKGROUND: Among patients in the emergency department, dyspnea is a common complaint and can
pose a diagnostic challenge. Biomarkers are used increasingly to improve diagnostic accuracy and aid with
prognostication in dyspneic patients. The purpose of this study was to examine the clinical utility of serum
procalcitonin (PCT) for the diagnosis of pneumonia in patients presenting to the emergency department
with dyspnea. A secondary objective was to evaluate the prognostic value of PCT for death to 1 year.
METHODS: This study pooled the patient populations of 2 prospective cohorts that previously enrolled
patients presenting to 2 urban emergency departments with dyspnea. A total of 453 patients had serum
samples available for biomarker analysis. Clinician certainty for the diagnosis of acutely decompensated
heart failure was reviewed. Discrimination, calibration, and net reclassification improvement for the
diagnosis of pneumonia as well as fatal outcomes were considered. The main outcome was accuracy of PCT
for diagnostic categorization of pneumonia. The prognostic value of PCT for survival to 1 year was a
secondary outcome.
RESULTS: Pneumonia alone was diagnosed in 30 patients (6.6%), heart failure without pneumonia in 212
patients (47%), and both diagnoses in 30 patients (6.6%). Procalcitonin concentrations were higher in
subjects with pneumonia (0.38 vs 0.06 ng/mL; P < .001). Area under the receiver operating characteristic
curve for the diagnosis of pneumonia based on PCT was 0.84 (95% confidence interval [CI], 0.77-0.91;
P < .001). Across all levels of clinician-based estimates of heart failure, PCT was sensitive and specific;
notably, in patients judged with diagnostic uncertainty (n¼ 70), a PCT value of 0.10 ng/mL had the optimal
balance of sensitivity and specificity (80% and 77%, respectively) for pneumonia. Adding PCT results to
variables predictive of pneumonia resulted in a net reclassification improvement of 0.54 (95% CI,
0.24-0.83; P < .001) for both up- and down-reclassifying events. In adjusted analyses, elevated PCT was a
predictor of 1-year mortality (hazard ratio 1.8; 95% CI, 1.4-2.3; P < .001) and was additive when elevated
in conjunction with natriuretic peptides for this application.
CONCLUSION: In emergency department patients with acute dyspnea, PCT is an accurate diagnostic marker
for pneumonia and adds independent prognostic information for 1-year mortality.
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Alba et al Procalcitonin in Patients with Dyspnea 97Of the 130 million annual visits to the emergency depart-
ment, pneumonia and acutely decompensated heart failure
rank among the top admitting diagnoses and represent the
diagnoses with the largest number of 30-day all-cause
readmissions, contributing to an estimated $4.3 billion
in annual hospital costs.1 In-hospital and 60- to 90-dayCLINICAL SIGNIFICANCE
 In emergency department patients with
acute dyspnea, procalcitonin is an ac-
curate diagnostic marker for pneumonia.
 When there is diagnostic uncertainty
between the diagnosis of heart failure
and pneumonia, procalcitonin provided
good discrimination for the diagnosis
and exclusion of pneumonia.
 Elevated procalcitonin is a predictor of
1-year mortality in patients with pneu-
monia and is additive when elevated in
conjunction with the natriuretic
peptides.mortality for heart failure are 8%
and 13%, respectively,2 and mor-
tality is increased to 20% when a
concomitant pneumonia is diag-
nosed.3 Many patients presenting
with dyspnea have multiple coex-
isting medical disorders that
complicate their diagnosis and
management. Diagnostic uncer-
tainty in this setting is associated
with longer hospital length of stay,
increased costs, and higher likeli-
hood for repeat hospitalization
or death.4 Further, delay of treat-
ments, such as antibiotics in pa-
tients with pneumonia or diuretics
for those with heart failure, has
been associated with increased
mortality.5,6 Consequently, early
and accurate diagnosis is critical.
Studies have demonstrated that biomarkers may supplement
judgment for diagnosis of heart failure7,8; for this application,
the natriuretic peptides are now widely used. For correct
diagnosis or exclusion of pneumonia, recent data have
examined the potential value of procalcitonin (PCT).9,10
In healthy individuals, serum levels of PCT are unde-
tectable. In states of bacterial infection, PCT messenger
RNA is upregulated, whereas PCT production is attenuated
by cytokines linked to viral infections11,12; PCT has thus
been proposed as a diagnostic biomarker for bacterial
infection. Although measurement of PCT has been exam-
ined in several clinical contexts, its use specifically in
patients with acute dyspnea is less explored. In the Bio-
markers in Acute Heart Failure (BACH) trial, data sup-
portive of PCT to correctly identify or exclude pneumonia in
patients with acute dyspnea were reported; additionally,
PCT showed prognostic value for mortality prediction to 90
days from presentation. Therefore, we sought to rigorously
examine the promising diagnostic and prognostic implica-
tions of PCT in patients with acute dyspnea.METHODS
The institutional review boards at each institution approved
of the study procedures (Partners Healthcare IRB, protocol
no. 2003P000080).Study Population
We examined the potential value of PCT in 2 populations of
patients presenting to the emergency department setting, theProBNP Investigation of Dyspnea in the Emergency
Department (PRIDE) study7 and the Biomonitoring and
Cardiorenal Syndrome in Heart Failure (BIONICS-HF)
study.13 A study flow diagram is demonstrated in Figure 1.
The methods and primary results for the PRIDE study
have been published previously.7 In the PRIDE Study(a single-center study of acute
dyspnea performed in Boston,
Mass), at the time of emergency
department evaluation, clinicians
were asked for their impression for
the presence of heart failure on a
continuous scale from 0 (“abso-
lutely certain not present”) to
100% (“absolutely certain to be
present”).14 Analytes previously
tested include amino-terminal
pro-B type natriuretic peptide
(NT-proBNP), mid-regional pro-atrial
natriuretic peptide (MR-proANP),
mid-regional pro-adrenomedullin
(MR-proADM),15 and soluble
(s)ST2.
The second cohort considered
was the BIONICS-HF Study
(NCT01570153).13 This popula-tion was drawn from consenting patients aged 18 years
who presented to the emergency department at either
Massachusetts General Hospital (Boston) or Ospedale
Sant’Andrea (Rome, Italy) with dyspnea due to heart failure.
To be enrolled, the emergency department physician judged
the patient as having certain heart failure.
As shown in Figure 1, from a potential total of 700
patients (599 patients from PRIDE and 101 patients from
BIONICS-HF), 453 patients had available blood samples
for biomarker analysis. Of these patients, 212 (47%) had a
final diagnosis of heart failure, 30 (6.5%) had a primary
diagnosis of pneumonia, and another 30 (6.5%) of the
patients with heart failure had a secondary diagnosis of
pneumonia, bringing the total to 60 (13%) patients with
pneumonia. Follow-up to 1 year was 100% complete on all
subjects in this analysis.Determination of Diagnosis
The methods for determination of diagnosis have been
published previously.7 The diagnosis of pneumonia was
based on local medical records and subsequently cross-
verified according to clinical practice guidelines.16,17 Man-
aging physicians and adjudicators were blind to natriuretic
peptide and PCT results.Blood Analysis
The NT-proBNP analysis was performed with a commer-
cially available immunoassay (Elecsys proBNP; Roche
Diagnostics, Indianapolis, Ind).7 Mid-regional-proANP,
Figure 1 Flow diagram of the present study, including final diagnoses. ACS ¼ acute coronary syn-
drome; ADHF ¼ acutely decompensated heart failure; BIONICS ¼ Biomonitoring and Cardiorenal
Syndrome in Heart Failure; COPD ¼ chronic obstructive pulmonary disease; PE ¼ pulmonary embolism;
PNA ¼ pnuemonia; PRIDE ¼ ProBNP Investigation of Dyspnea in the Emergency Department.
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System (BRAHMS AG, Hennigsdorf, Germany), whereas
sST2 was assayed using a high-sensitivity enzyme-linked
immunosorbent assay (Presage ST2; Critical Diagnostics,
San Diego, Calif). The detection limit for PCT was 0.02 ng/mL;
interassay coefficients of variation for PCT concentrations
0.30 ng/mL are below 6%. The intra-assay and interassay
coefficients of variation for each marker have been reported
previously.7,15Statistical Analysis
Baseline characteristics of the study population, stratified by
PCT concentration at presentation, were calculated.
Continuous variables were summarized as mean  standard
deviation if normally distributed, whereas non-normally
distributed continuous variables were summarized as me-
dian and interquartile range. Kolmogorov-Smirnov testing
identified states of non-normality. Variables were compared
using the Student t test or c2 test as appropriate, whereas the
Mann-Whitney U test was used for continuous variables in
the states of non-normality.
Diagnostic accuracy of PCT was assessed; performance
of PCT at its optimal diagnostic threshold was assessed
across clinician-expressed likelihood for the diagnosis of
heart failure as the primary cause of dyspnea; as describedby Green et al,14 results on this scale between 25% and 75%
were defined as clinical uncertainty. In those patients with
dyspnea and estimates >75%, clinicians were leaning to-
ward heart failure, whereas by proxy a percent likelihood
<25% indicates clinical suspicion for an alternative diag-
nosis, such as pneumonia. Following this step, logistic
regression models were developed to identify independent
predictors of pneumonia. Odds ratios and 95% confidence
intervals (CIs) were generated. All non-normal covariates
were log-transformed. Logistic models were run for the
multivariable model, once with PCT and once without PCT,
with C-statistic for each step compared. After discrimination
analysis, we considered continuous net reclassification
improvement (NRI) as described by Pencina et al,18 using
999 bootstrap replications to estimate the 95% CI for NRI.
To identify independent predictors of mortality, we used
stepwise Cox proportional hazards modeling, including
clinical variables as well as log-transformed results for NT-
proBNP, MR-proANP, MR-proADM, sST2, and PCT.
Variables with univariate significance  .10 were considered
for the multivariable model. The proportion of hazards was
checked. C-statistics for models with and without PCT were
calculated, and NRI was again measured. Cumulative
hazard curves with PCT alone as well as together with
MR-proANP were constructed. Last, outcomes as a function
of PCT result and antibiotic prescription were assessed.
Table 1 Baseline Characteristics of the Study Subjects as a Function of Baseline Procalcitonin (PCT) Concentration
Characteristic
PCT < 0.10 ng/mL
(n ¼ 317)
PCT  0.10 ng/mL
(n ¼ 136) P Value
Age 61.7  17.1 72.7  12.7 <.001
Sex (% male) 155 (48.9) 79 (58.1) .09
Past history
Diabetes mellitus 89 (28.1) 54 (39.7) .02
Prior heart failure 81 (25.6) 58 (42.6) <.001
Obstructive airway disease 36 (11.4) 33 (24.3) .001
Hypertension 162 (51.1) 93 (68.4) .001
Coronary artery disease 95 (30.0) 54 (39.7) .06
Prior myocardial infarction 48 (15.1) 28 (20.6) .20
Medications on presentation
b-Blocker 140 (44.2) 75 (55.1) .04
Loop diuretic 95 (30.0) 64 (47.1) .001
Digoxin 29 (9.1) 18 (13.2) .30
ACE inhibitor 73 (23.0) 34 (25.0) .70
Angiotensin II receptor blocker 25 (7.9) 14 (10.3) .50
Aldosterone antagonist 15 (4.7) 13 (9.6) .08
Aspirin 120 (37.9) 57 (41.9) .50
Nitrate 38 (12.0) 33 (24.3) .002
Inhaled short-acting b-agonist 81 (25.6) 38 (27.9) .70
Advair 25 (7.9) 23 (16.9) .007
Steroid, systemic 16 (5.0) 5 (3.7) .70
Antibiotics, chronic 4 (1.3) 6 (4.4) .07
Inhaled long-acting b-agonist 13 (4.1) 10 (7.4) .20
Inhaled anticholinergic 32 (10.1) 11 (8.1) .60
Combivent 13 (4.1) 2 (1.5) .30
Symptoms
Paroxysmal nocturnal dyspnea 44 (13.9) 25 (18.4) .30
Orthopnea 69 (21.8) 49 (36.0) .002
Edema 72 (22.7) 51 (37.5) .002
Chest pain 135 (42.6) 37 (27.2) .003
Cough 116 (36.6) 54 (39.7) .60
Fever 21 (7.5) 19 (22.4) <.001
NYHA class .002
I 39 (12.3) 7 (5.1)
II 103 (32.5) 32 (23.5)
III 94 (29.7) 41 (30.1)
IV 81 (25.6) 56 (41.2)
LVEF, last known 57  17 55  15 .07
Physical examination
Temperature (F) 96.7  31.2 98.1  30.7 .03
Body mass index (kg/m2) 28.7  6.6 28.5  8.1 .30
Heart rate (beats/min) 84  22 93  24 <.001
Systolic blood pressure (mm Hg) 140  31 137  40 .09
Jugular venous distension 37 (11.7) 28 (20.6) .02
S3 gallop 5 (1.6) 2 (1.5) 1.0
Rales 89 (28.1) 80 (58.8) <.001
Edema 92 (29.1) 63 (46.3) .001
Chest radiography
Interstitial edema 55 (17.4) 49 (36.0) <.001
Infiltrate 38 (12.0) 33 (24.3) .002
Cardiomegaly 15 (3.8) 35 (16.7) <.001
Pleural effusion 45 (14.2) 46 (33.8) <.001
Laboratory results, median (IQR)
GFR (mL/min/1.73 m2) 77.8 (60.0-94.1) 50.5 (35.1-72.3) <.001
WBC 8.0 (6.5-10.4) 10.3 (7.3-13.3) <.001
Hemoglobin (g/dL) 13.3 (12.0-14.7) 11.5 (10.0-12.8) <.001
NT-proBNP (pg/mL) 388 (72-2395) 2685 (910-10091) <.001
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Table 1 Continued
Characteristic
PCT < 0.10 ng/mL
(n ¼ 317)
PCT  0.10 ng/mL
(n ¼ 136) P Value
MR-proANP (pmol/L) 96.4 (36.2-249.4) 309.6 (157.4-552.4) <.001
MR-pro ADM (nmol/L) 0.42 (0.20-0.83) 1.37 (0.84-2.22) <.001
sST2 (ng/mL) 23.5 (13.7-44.3) 97.7 (51.0-190.1) <.001
Values are number (percentage) or mean  standard deviation, unless otherwise noted.
ACE ¼ angiotensin-converting enzyme; GFR ¼ glomerular filtration rate; IQR ¼ interquartile range; LVEF ¼ left ventricular ejection fraction;
MR-proADM ¼ mid-regional pro-adrenomedullin; MR-proANP ¼ mid-regional pro-atrial natriuretic peptide; NT-proBNP ¼ amino-terminal pro-B type
natriuretic peptide; NYHA ¼ New York Heart Association; sST2 ¼ soluble ST2; WBC ¼ white blood cell.
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performed using Analyse It software (Leeds, United
Kingdom), whereas all other statistical analyses were
performed using either PASW Statistics, version 17.0
(Chicago, Ill) or SAS (version 9.2; SAS Institute, Cary,
NC). All P values are 2-sided, with a value of < .05
considered significant.RESULTS
As noted and depicted in Figure 1, of the 453 patients in the
present study, 212 (47%) had a final diagnosis of heart
failure, 30 (6.5%) had a primary diagnosis of pneumonia,
and another 30 (6.5%) of the patients with heart failure
had a secondary diagnosis of pneumonia, bringing the
total to 60 patients (13%) with pneumonia.Baseline Characteristics
A PCT value of 0.10 ng/mL was found to have the best test-
operating characteristics for the diagnosis of pneumonia.
Baseline characteristics of the study population stratified by
PCT value of <0.10 or 0.10 ng/mL are detailed in
Table 1.PCT and the Diagnosis of Pneumonia
Median [interquartile range] concentrations of PCT were
higher in those with pneumonia (0.38 [0.12-1.40] ng/mL)
compared with those without (0.06 [0.04-0.09] ng/mL;
P < .001 for difference; Supplemental Figure 1, available
online). Supplemental Figure 2 (available online) depicts
the various diagnoses and PCT concentrations measured inTable 2 Operating Characteristics of Procalcitonin for the Diagnosis
Categories of Clinician-Estimated Likelihood for Heart Failure
Clinician Estimate of HF Likelihood Sensitivity (%
Overall 78
Unlikely (<25%), n ¼ 244, 33 pneumonia 70
Uncertain (25%-75%), n ¼ 70, 10 pneumonia 80
Likely (>75%), n ¼ 139, 17 pneumonia 95
In patients judged with low likelihood for heart failure (hence higher likelihoo
pneumonia, whereas in those with high likelihood for heart failure, PCT had exce
indecision, PCT had an optimal balance of sensitivity and specificity.
HF ¼ heart failure; NPV ¼ negative predictive value; PPV ¼ positive predicthe study cohort. Notably, PCT concentrations were
particularly highest in those with comorbid heart failure
and pneumonia (0.62 [0.28-3.20] ng/mL); conversely,
those with both heart failure and pneumonia (n ¼ 30) had
the highest concentrations of natriuretic peptides (results not
shown).
In ROC curves, PCT had an area under the curve (AUC)
of 0.84 (95% CI, 0.77-0.91; P < .001). An optimal PCT cut-
off for the diagnosis of pneumonia was 0.10 ng/mL; at this
threshold, PCT had an excellent balance of sensitivity,
specificity, positive predictive value, and negative predictive
value (NPV), as shown in Table 2. Notably, across clinician
estimates for heart failure, PCT performed consistently and
in a manner consistent with Bayesian probabilities
(Table 2): when clinician estimate for heart failure
likelihood was <25% (ie, less likely to be heart failure),
PCT had highest specificity (85%), whereas in those
patients judged to have >75% likelihood for heart failure
(n ¼ 139), PCT had highest sensitivity (95%) and
NPV (99%); more than half (n ¼ 74, 53.2%) of subjects
judged as high likelihood for heart failure had PCT values
<0.10 ng/mL. Finally, in challenging cases when clinician
estimate of heart failure likelihood was between 25% and
75% (defined as “indecision”), PCT had balanced
sensitivity and specificity.
When examining patients a posteriori in those with heart
failure, PCT had an AUC of 0.92 (95% CI, 0.87-0.98;
P < .001) for pneumonia; at 0.10 ng/mL, PCT had 97%
sensitivity, 69% specificity, 36% positive predictive value,
and 99% NPV, confirming utility to exclude pneumonia in
those with heart failure; the threshold providing comparable
specificity (97%) for pneumonia in heart failure wasof Pneumonia in the Entire Group and in Previously Established
) Specificity (%) PPV (%) NPV (%)
80 39 96
85 42 95
77 36 96
57 27 99
d for pulmonary diagnoses), procalcitonin (PCT) had highest specificity for
llent negative predictive value (NPV) for pneumonia. In those judged with
tive value.
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peptides and PCT for evaluation of dyspnea is shown in
Supplemental Figure 3 (available online).
In logistic regression to identify predictors of pneumonia,
ln-transformed PCT remained as an independent variable in
multivariable models (odds ratio 2.2; 95% CI, 1.4-3.6;
Table 3); univariate results for predictors of pneumonia are
shown in Supplemental Table 1 (available online). The
C-statistic of the base clinical model without PCT was
0.94 (95% CI, 0.90-0.97), which rose to 0.95 (95% CI,
0.91-0.98) after PCT was added (P ¼ .35).
Continuous NRI was performed comparing the model
without PCT with a model incorporating PCT data. Addition
of PCT results was associated with a significant NRI of 0.54
(95% CI, 0.24-0.83; P < .001). Overall, the model including
PCT moved 25% of pneumonia into a higher probability
category (P ¼ .08), and 29% of non-pneumonia into a lower
probability category (P < .001).Predictors of Mortality
There were 40 deaths during the first 90 days, and 80 deaths
by 1 year. Concentrations of presentation PCT were higher
in 9- day decedents compared with survivors (0.13
[0.08-0.41] vs 0.06 [0.04-0.10] ng/mL; P < .001); in a
similar manner, PCT values at presentation were higher in
those dead at 1 year as well (0.12 [0.08-0.38] vs 0.06
[0.04-0.10] ng/mL; P < .001).
Univariate predictors of death at 90 days and 1 year are
shown in Supplemental Table 2; multivariable predictors
of death at 1 year are shown in Supplemental Table 3
(both available online). At 90 days, in adjusted models,
presence of a heart murmur on examination (hazard ratio
[HR] 3.5; 95% CI, 1.5-8.3; P < .001) as well as
ln-transformed concentrations of sST2 (HR 3.0; 95% CI,
1.9-4.9; P < .001) emerged as predictors of 90-day mor-
tality. At 1 year, PCT was an independent predictor death in
adjusted models (HR 1.8; 95% CI, 1.4-2.3; P < .001), along
with concentrations of MR-proANP (HR 1.8; 95% CI
1.2-2.6; P ¼ .004).
To determine the incremental value of PCT beyond a
base model, we again evaluated change in C-statistic;
adding results for PCT increased the C-statistic for mortalityTable 3 Multivariable Predictors of a Diagnosis of Pneumonia Along
Variable Odds Ratio (95% CI)
Aspirin use 0.26 (0.08-0.83)
Chest radiograph infiltrate or pneumonia 12.5 (4.6-34.1)
Cough 6.1 (2.1-18.2)
Fever 4.3 (1.5-12.7)
PCT 2.2 (1.4-3.6)
sST2 2.9 (1.6-5.3)
Both PCT and sST2 were entered as log-transformed variables. Operating char
ng/mL, respectively.
CI ¼ confidence intervals; NPV ¼ negative predictive value; PCT ¼ procalcit
sST2 ¼ soluble ST2.from 0.77 to 0.80 (P ¼ .02). Continuous NRI yielded a net
reclassification improvement of 41% (95% bootstrap CI,
8-74; P < .001), exclusively driven by down-classification
of risk in 44%.
In cumulative hazard analyses PCT  0.10 ng/mL was
associated with higher cumulative hazard both at 90 days
and 1 year (Figure 2). Because both PCT and MR-proANP
were significant predictors of mortality at 1 year, we found
greater precision in time to first event analyses considering
the 2 in a multiple marker strategy using a previously
derived threshold for MR-proANP (logerank P < .001;
Supplemental Figure 4, available online).15
Of the patients with pneumonia, the great majority
(87.3%) were treated with antibiotics during their index
hospitalization, whereas the minority (25.1%) of those
without pneumonia also were treated. We found no asso-
ciation between outcome as a function of PCT concentration
at presentation and subsequent antibiotic prescription status.
Changing PCT thresholds did not affect the results (results
not shown).DISCUSSION
Among patients with acute dyspnea in the emergency
department setting, we found PCT provided good discrim-
ination for the diagnosis and exclusion of pneumonia, and
both up- and down-classified likelihood for pneumonia
diagnosis. Importantly, PCT concentrations allowed for
accurate diagnosis and exclusion of pneumonia in those
patients with comorbid heart failure; early recognition and
treatment of such patients is of importance given their
higher risk. Finally, PCT values were prognostic for death
by 1 year, showing additive value with MR-proANP for this
application.
Biomarkers are used increasingly in the routine practice
of clinical medicine. A burgeoning literature has demon-
strated occasionally conflicting utility of PCT in the diag-
nosis and management of infectious syndromes including
pneumonia.9,10,19-24 Our results are important, in that we
not only showed that PCT provides useful discriminatory
information for pneumonia, but does so in patients judged
with clinical indecision, where PCT provided optimal
operating characteristics. As would be expected on the basiswith Operating Characteristics for the Diagnosis of Pneumonia
P Value Sn (%) Sp (%) PPV (%) NPV (%)
.02 29 59 10 84
<.001 51 90 45 92
.001 60 66 22 91
.009 38 93 47 92
.001 78 80 39 96
<.001 81 68 29 96
acteristics for PCT and sST2 refer to optimal cut-offs of 0.10 ng/mL and 49
onin; PPV ¼ positive predictive value; Sn ¼ sensitivity; Sp ¼ specificity;
Figure 2 Cumulative hazard for death at (A) 90 days and (B) 1 year as a function of procalcitonin (PCT)
concentrations.
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high likelihood for heart failure, PCT was very sensitive
(providing excellent NPV to exclude pneumonia in a
majority of such subjects), whereas in those with a low
likelihood for heart failure (hence high likelihood for a
pulmonary diagnosis), an elevated PCT was highly specific
for pneumonia.
A notable finding in our study was, when measured alone
or together with MR-proANP in a multimarker strategy,
higher PCT values were associated with shorter time to first
event in cumulative hazards analysis. Pneumonia risk models
such as the CURB-6525 and Pneumonia Severity Index26may
be useful for triage decision making; however, their use may
be cumbersome. Future efforts should compare the individual
and additive value of PCT with established pneumonia risk
scores; we lacked some variables in each model to examine
this question in the present analysis.
Our results extend those of the BACH study with
rigorous diagnostic and prognostic evaluation; although our
findings are in alignment with BACH, we found higher
AUC in ROC analyses (0.84 vs 0.72) and also a greater
degree of reclassification in NRI assessment. Importantly,
we extend the BACH prognosis assessment of PCT
by adding substantially more complicated diagnostic
assessment in those with heart failure, more complex
survival analyses that include discrimination and NRI and
show value of PCT out to a follow-up to 1 year, as opposed
to 90 days, and we also compared PCT with a broader range
of contemporary biomarkers.
A limitation of our study is its modest size, which limits
the power of statistical calculations. The number of patients
diagnosed with pneumonia was low relative to the number
of patients with heart failure. Although both cohorts were
studied prospectively with a priori power assumptions for
their respective primary outcomes, our retrospective anal-
ysis for our primary and secondary outcomes occurred a
posteriori. We lack serial measurement of PCT or other
biomarkers. Last, we had few patients with elevated PCT
that went untreated with antibiotics.CONCLUSION
In an era of increasing clinical complexity and healthcare
costs, biomarkers represent an important tool for both
diagnostic and prognostic efficiency. The potential role for
PCT is broad—from predicting mortality risk to opti-
mizing diagnostic accuracy for pneumonia and guiding
antimicrobial use in patients with concomitant heart fail-
ure. Our results support the diagnostic and prognostic
value of PCT in acute dyspnea, adding substantially to
clinical variables and other biomarkers for these
applications.
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Supplemental Figure 1 Box and whisker plots of procalcitonin (PCT) as a function of pneu-
monia (PNA) vs alternative diagnosis. Median concentrations of procalcitonin were higher in those
with pneumonia; boxes refer to the 25th and 75th percentiles, and whiskers the 5th and 95th
percentiles. Outliers are shown as open circles, extremes as stars.
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Supplemental Figure 2 Median concentrations of procalcitonin as a function of various
diagnoses in the cohort. Values for procalcitonin were considerably higher in those with a diag-
nosis of pneumonia (PNA). Boxes refer to the 25th and 75th percentiles, and whiskers the 5th and
95th percentiles. Outliers are shown as open circles, extremes as stars. ADHF ¼ acutely
decompensated heart failure; COPD ¼ chronic obstructive pulmonary disease; MI ¼ myocardial
infarction; UAP ¼ unstable angina pectoris.
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Supplemental Figure 3 Suggested diagnostic strategy for use of procalcitonin (PCT) in acute dyspnea,
combining measurement with (A) amino-terminal pro-B type natriuretic peptide (NT-proBNP) or
(B) mid-regional pro-atrial natriuretic peptide (MR-proANP). Using either natriuretic peptide, added use of
procalcitonin allowed for even more refined identification or exclusion of heart failure (ADHF), pneumonia
(PNA), or both diagnoses. Diagnostic cut-offs for NT-proBNP and MR-proANP are as previously
defined.15,27,28
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Supplemental Figure 4 Cumulative hazard for death at 1 year as a function of procalcitonin
(PCT) and mid-regional pro-atrial natriuretic peptide (MR-proANP) concentrations. The 2 bio-
markers provided additive prognostic value, reclassifying in time to first event analyses.
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Supplemental Table 1 Univariate Predictors of a Final Diag-
nosis of Pneumonia
Univariate Variable
Odds Ratio
(95% CI) P Value
ACE 0.82 (0.43-1.6) .55
ARB 0.49 (0.15-1.6) .25
ASA 0.58 (0.32-1.0) .07
Acutely decompensated HF 1.3 (0.76-2.2) .34
Advair 2.0 (0.97-4.2) .06
Aldactone 0.73 (0.21-2.5) .62
b-Blocker 0.81 (0.47-1.4) .43
CXR infiltrate or pneumonia 9.3 (5.1-16.8) <.001*
CXR cephalization of vessels 2.1 (0.21-20.3) .53
CXR interstitial edema 1.5 (0.86-2.8) .15
CXR pleural effusion 1.7 (0.95-3.2) .07
Chest pain 0.42 (0.22-0.79) .007
Chronic antibiotics 4.3 (1.2-15.8) .03
Combivent 0.43 (0.06-3.4) .42
Cough 3.0 (1.7-5.1) <.001*
Digoxin 1.3 (0.58-2.9) .52
ECG LBBB 1.5 (0.58-3.7) .41
ECG LVH 0.72 (0.16-3.2) .67
ECG atrial fib flutter 1.8 (0.96-3.5) .07
ECG sinus rhythm 0.64 (0.37-1.1) .11
Edema 0.88 (0.50-1.6) .66
Fever 8.0 (3.9-16.7) <.001*
HCTZ 0.58 (0.17-2.0) .38
HJR 0.72 (0.16-3.2) .67
History of CAD 0.72 (0.40-1.3) .28
History of COPD 1.9 (1.0-3.7) .04
History of arrhythmia 1.1 (0.61-2.1) .69
History of diabetes 0.77 (0.43-1.4) .40
History of hypertension 0.77 (0.45-1.3) .34
History of prior HF 1.1 (0.60-1.9) .84
History of prior MI 0.58 (0.25-1.3) .20
Hydralazine 0.88 (0.11-7.3) .91
Inhaled anticholinergic 1.7 (0.79-3.8) .17
Inhaled short acting b-agonist 2.1 (1.2-3.6) .01
Inhaled corticosteroid 2.0 (0.85-4.5) .12
Inhaled long acting b-agonist 1.3 (0.44-4.0) .62
JVD 0.85 (0.38-1.9) .69
Leukotriene modifier 0.88 (0.20-4.0) .87
Loop diuretic 0.99 (0.57-1.7) .97
Lower extremity edema 0.46 (0.23-0.94) .03
Murmur 0.85 (0.37-2.0) .70
Nitrate 0.76 (0.34-1.7) .49
Orthopnea 1.2 (0.64-2.1) .62
PND 1.2 (0.60-2.5) .60
Pulmonary rales 2.8 (1.6-4.8) <.001*
S4Gallop 1.2 (0.14-10.8) .84
Sex 1.1 (0.65-1.9) .69
Systemic steroid 2.6 (0.98-7.1) .05
Wheezing 1.2 (0.68-2.3) .47
Age, log-transformed 3.2 (1.1-9.1) .03
BMI, log-transformed 0.34 (0.10-1.2) .09
NT-proBNP, log-transformed 1.3 (1.1-1.5) <.001*
BUN, log-transformed 1.6 (1.00-2.5) .05
Creatinine, log-transformed 2.3 (1.2-4.3) .01
Supplemental Table 1 Continued
Univariate Variable
Odds Ratio
(95% CI) P Value
MDRD creatinine clearance,
log-transformed
0.49 (0.29-0.83) .008
Diastolic BP, log-transformed 0.45 (0.12-1.7) .24
ECG QRS duration, log-transformed 1.0 (0.34-3.2) .95
Glucose, log-transformed 2.4 (1.3-4.7) .009
Hb, log-transformed 0.29 (0.07-1.1) .08
Last known EF, log-transformed 0.58 (0.26-1.3) .18
PCT, log-transformed 3.3 (2.5-4.4) <.001
MR proADM, log-transformed 2.5 (1.7-3.6) <.001*
MR proANP, log-transformed 1.4 (1.1-1.8) .005
Pulse, log-transformed 27.3 (8.2-91.0) <.001*
Systolic BP, log-transformed 0.32 (0.12-0.89) .03
Sodium, log-transformed 1.9 (0.22-15.6) .56
ST2, log-transformed 3.6 (2.6-5.0) <.001*
WBC, log-transformed 3.4 (1.9-6.1) <.001*
NYHA: class II 1.1 (0.35-3.6) .85
NYHA: class III 1.3 (0.41-4.2) .65
NYHA: class IV 3.1 (1.0-9.2) .05
NYHA: class I 1.0 (reference) —
History of tobacco use: 1 0.33 (0.14-0.79) .01
History of tobacco use: 2 0.58 (0.25-1.3) .19
History of tobacco use: 3 0.51 (0.20-1.3) .17
History of tobacco use: 0 1.0 (reference) —
ACE ¼ angiotensin converting enzyme; ARB ¼ angiotensin receptor
blocker; ASA¼ aspirin; BMI¼ body mass index; BP¼ blood pressure; BUN
¼ blood urea nitrogen; CAD ¼ coronary artery disease; COPD ¼ chronic
obstructive pulmonary disease; CXR ¼ chest x-ray; ECG ¼ electrocardio-
gram; EF ¼ ejection fraction; Hb ¼ hemoglobin; HCTZ ¼ hydrochlorothi-
azide; HF ¼ heart failure; HJR ¼ hepatojugular reflex; JVD ¼ jugular
venous distention; LBBB¼ left bundle branch block; LVH¼ left ventricular
hypertrophy; MDRD ¼ Modification of Diet in Renal Disease;
MI ¼ myocardial infarction; NYHA ¼ New York Heart Association;
PND ¼ paroxysmal nocturnal dyspnea; WBC ¼ white blood cell.
*Indicates statistically significant.
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Supplemental Table 2 Univariate Predictors of Mortality at 90 Days and 1 Year
Univariate Variable
90-Day Mortality
Hazard Ratio (95% CI)
90-Day
P Value
1-Year Mortality
Hazard Ratio (95% CI)
1-Year
P Value
ACE 1.4 (0.72-2.8) .32 1.2 (0.72-1.9) .51
ARB 0.87 (0.27-2.8) .81 1.2 (0.58-2.5) .63
ASA 1.4 (0.76-2.6) .27 1.1 (0.71-1.7) .63
Acutely decompensated HF 4.2 (2.0-8.8) <.001* 3.9 (2.3-6.4) <.001*
Advair 1.2 (0.47-3.1) .71 1.2 (0.63-2.4) .54
Aldactone 2.2 (0.87-5.7) .10 2.4 (1.2-4.6) .01
b-Blocker 2.4 (1.2-4.6) .01 1.9 (1.2-2.9) .007
CXR infiltrate or pneumonia 2.1 (1.1-4.3) .03 1.3 (0.76-2.3) .32
CXR cephalization of vessels 0 .99 1.3 (0.18-9.5) .78
CXR interstitial edema 3.3 (1.8-6.1) <.001* 3.0 (1.9-4.7) <.001*
CXR pleural effusion 3.2 (1.7-6.0) <.001* 2.7 (1.7-4.3) <.001*
Chest pain 0.60 (0.30-1.2) .16 0.76 (0.48-1.2) .26
Chronic antibiotics 2.7 (0.65-11.2) .17 2.7 (1.0-7.5) .05
Combivent 0.72 (0.10-5.2) .74 1.1 (0.36-3.6) .83
Cough 0.62 (0.31-1.2) .18 0.56 (0.34-0.93) .02
Digoxin 2.3 (1.1-5.0) .04 2.2 (1.3-3.9) .005
ECG LBBB 1.5 (0.54-4.3) .42 1.6 (0.76-3.3) .22
ECG LVH 2.6 (0.92-7.2) .07 2.5 (1.2-5.5) .02
ECG atrial fib flutter 1.9 (0.91-3.8) .09 1.8 (1.1-2.9) .03
ECG sinus rhythm 0.39 (0.21-0.72) .003* 0.56 (0.36-0.88) .01
Edema 2.2 (1.2-4.2) .01 2.1 (1.3-3.2) .001
Fever 1.8 (0.63-5.5) .27 1.8 (0.88-3.7) .11
HCTZ 1.8 (0.69-4.5) .24 1.9 (0.96-3.6) .07
HJR 3.5 (1.4-8.8) .009* 2.6 (1.2-5.7) .01
History of CAD 1.4 (0.72-2.5) .35 1.5 (0.99-2.4) .05
History of COPD 1.2 (0.52-2.7) .70 1.2 (0.67-2.1) .55
History of arrhythmia 1.8 (0.92-3.4) .09 1.7 (1.1-2.8) .02
History of diabetes 1.5 (0.79-2.8) .22 1.4 (0.92-2.3) .12
History of hypertension 1.5 (0.78-2.8) .23 1.5 (0.95-2.4) .08
History of prior HF 2.1 (1.1-3.9) .02 2.3 (1.5-3.6) <.001*
History of prior MI 1.3 (0.59-2.8) .54 1.2 (0.67-2.1) .58
Hydralazine 1.5 (0.21-11.1) .68 0.73 (0.10-5.2) .75
Inhaled anticholinergic 0.49 (0.12-2.0) .32 1.2 (0.59-2.4) .63
Inhaled short acting b-agonist 0.69 (0.32-1.5) .34 0.79 (0.47-1.3) .37
Inhaled corticosteroid 0.62 (0.15-2.6) .50 0.61 (0.22-1.7) .34
Inhaled long acting b-agonist 0.46 (0.06-3.4) .45 0.96 (0.35-2.6) .94
JVD 2.3 (1.2-4.7) .02 1.6 (0.92-2.8) .10
Leukotriene modifier 0 .99 0.32 (0.04-2.3) .26
Loop diuretic 1.5 (0.83-2.9) .17 1.9 (1.2-2.9) .006
Lower extremity edema 1.7 (0.87-3.1) .12 1.7 (1.1-2.7) .02
Murmur 2.1 (1.0-4.4) .05 2.8 (1.7-4.5) <.001*
Nitrate 1.6 (0.76-3.3) .22 1.3 (0.74-2.3) .38
Orthopnea 2.2 (1.2-4.2) .01 2.2 (1.4-3.4) <.001*
PND 1.2 (0.52-2.6) .70 1.5 (0.90-2.6) .12
Pulmonary rales 3.0 (1.6-5.6) <.001* 2.5 (1.6-3.9) <.001*
S3Gallop 5.8 (1.8-18.9) .003* 4.8 (1.8-13.2) .002
Sex 1.1 (0.61-2.1) .69 1.0 (0.67-1.6) .89
Systemic steroid 0.52 (0.07-3.8) .52 1.7 (0.74-3.9) .21
Wheezing 0.57 (0.24-1.3) .20 0.72 (0.41-1.3) .26
Age, log-transformed 22.8 (4.0-129.5) <.001* 17.8 (5.5-57.7) <.001*
BMI, log-transformed 0.20 (0.05-0.89) .03 0.37 (0.14-1.0) .06
NT-proBNP, log-transformed 1.5 (1.2-1.8) <.001* 1.5 (1.3-1.7) <.001*
BUN, log-transformed 2.6 (1.5-4.4) <.001* 2.6 (1.8-3.7) <.001*
Creatinine, log-transformed 1.9 (0.91-3.9) .09 2.2 (1.3-3.6) .003
MDRD creatinine clearance, log-transformed 0.50 (0.28-0.89) .02 0.45 (0.30-0.66) <.001*
Diastolic BP, log-transformed 0.50 (0.11-2.3) .38 0.34 (0.11-1.0) .05
104.e6 The American Journal of Medicine, Vol 129, No 1, January 2016
Supplemental Table 2 Continued
Univariate Variable
90-Day Mortality
Hazard Ratio (95% CI)
90-Day
P Value
1-Year Mortality
Hazard Ratio (95% CI)
1-Year
P Value
ECG QRS duration, log-transformed 2.7 (0.81-9.2) .10 2.2 (0.97-5.2) .06
Glucose, log-transformed 1.6 (0.74-3.5) .24 1.8 (1.1-3.1) .03
Hb, log-transformed 0.14 (0.04-0.52) .003 0.12 (0.05-0.29) <.001*
Last known EF, log-transformed 0.39 (0.19-0.83) .01 0.58 (0.33-1.0) .06
PCT, log-transformed 1.5 (1.3-1.8) <.001* 1.5 (1.3-1.7) <.001*
MR proADM, log-transformed 3.5 (2.2-5.6) <.001* 2.9 (2.1-3.8) <.001*
MR proANP, log-transformed 2.3 (1.7-3.2) <.001* 2.1 (1.7-2.6) <.001*
Pulse, log-transformed 3.5 (1.0-12.0) .04 1.8 (0.78-4.1) .17
Systolic BP, log-transformed 0.64 (0.22-1.8) .40 0.56 (0.29-1.1) .09
Sodium, log-transformed 1.2 (0.36-4.0) .77 0.82 (0.54-1.2) .34
ST2, log-transformed 2.6 (1.9-3.5) <.001* 2.2 (1.8-2.7) <.001*
WBC, log-transformed 1.8 (0.99-3.2) .05 1.4 (0.86-2.1) .19
NYHA: class II 0.68 (0.17-2.7) .59 0.75 (0.23-2.5) .64
NYHA: class III 1.5 (0.43-5.4) .51 2.7 (0.96-7.7) .06
NYHA: class IV 2.1 (0.62-7.1) .23 3.4 (1.2-9.6) .02
NYHA: class I 1.0 (reference) — 1.0 (reference) —
History of tobacco use: 1 0.34 (0.15-0.79) .01 0.46 (0.24-0.88) .02
History of tobacco use: 2 0.24 (0.10-0.60) .002 0.42 (0.22-0.81) .01
History of tobacco use: 3 0.36 (0.14-0.98) .05 0.42 (0.19-0.91) .03
History of tobacco use: 0 1.0 (reference) — 1.0 (reference) —
ACE ¼ angiotensin converting enzyme; ARB ¼ angiotensin receptor blocker; ASA ¼ aspirin; BMI ¼ body mass index; BP ¼ blood pressure; BUN ¼ blood
urea nitrogen; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; CXR ¼ chest x-ray; ECG ¼ electrocardiogram; EF ¼ ejection
fraction; Hb ¼ hemoglobin; HCTZ ¼ hydrochlorothiazide; HF ¼ heart failure; HJR ¼ hepatojugular reflex; JVD ¼ jugular venous distention; LBBB ¼ left
bundle branch block; LVH ¼ left ventricular hypertrophy; MDRD ¼ Modification of Diet in Renal Disease; MI ¼ myocardial infarction; NYHA ¼ New York Heart
Association; PND ¼ paroxysmal nocturnal dyspnea; WBC ¼ white blood cell.
*Indicates statistically significant.
Supplemental Table 3 Multivariable Predictors of Death at 1
Year
Variable Hazard Ratio (95% CI) P Value
Hepatojugular reflux 3.5 (1.1-11.9) .04
Murmur 4.8 (2.5-9.4) <.001
Diastolic blood pressure 11.8 (3.1-44.8) <.001
Systolic blood pressure 0.02 (0.003-0.14) <.001
PCT 1.8 (1.4-2.3) <.001
MR-proANP 1.8 (1.2-2.6) .004
Continuous variables were log-transformed.
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